https://www.taxtmi.com/caselaws?id=305667 The Supreme Court upheld the High Court's decision to dismiss the petition under Section 482 Cr.P.C., allowing the company directors to prove their lack of involvement in the manufacturing of a defective drug before the Trial Court. The Court emphasized the need for evidence to determine liability under Section 34(2) of the Drugs & Cosmetics Act, highlighting the seriousness of public health implications. The appeal was dismissed, affirming the importance of proving active involvement for directorial liability in cases of defective drugs. en-us Fri, 06 Aug 2010 00:00:00 +0530 Mon, 19 Dec 2022 14:21:28 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=305667 The Supreme Court upheld the High Court's decision to dismiss the petition under Section 482 Cr.P.C., allowing the company directors to prove their lack of involvement in the manufacturing of a defective drug before the Trial Court. The Court emphasized the need for evidence to determine liability under Section 34(2) of the Drugs & Cosmetics Act, highlighting the seriousness of public health implications. The appeal was dismissed, affirming the importance of proving active involvement for directorial liability in cases of defective drugs. Case-Laws Indian Laws Fri, 06 Aug 2010 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=305667